Portfolio companies are not underperforming because they lack talent, capital, or market. They are underperforming because the specific constraint limiting commercial growth has never been formally identified. Wiremap delivers the portfolio growth intelligence that answers the questions boards ask and investors cannot currently answer.
Every board meeting surfaces the same questions. The team gives honest answers based on their own view of the problem. The honest answer is almost always a departmental explanation for a cross-functional constraint. Wiremap is the only source of intelligence that can answer these questions with evidence rather than inference.
These patterns are consistent across B2B portfolio companies at seed and Series A. Each one is identifiable through a structured diagnostic before it costs the company and the portfolio significant capital.
Wiremap delivers the highest value at three specific moments in the portfolio company lifecycle. Each one is a decision point where the intelligence changes the quality of the decision by an order of magnitude.
The process is entirely asynchronous. The founder completes a structured intake. Wiremap delivers the intelligence within 14 business days. You receive an investor summary of the primary finding. The next board conversation starts from the diagnosis rather than the symptom.
| Intelligence Product | Best used when | What investor receives | Price |
|---|---|---|---|
| GTM Clarity Intelligence | Portfolio company is pre-revenue to $300K ARR and commercial traction is inconsistent | One-page investor finding summary with root cause and recommended actions | $499 |
| GTM Risk Intelligence | Company is $200K to $2M ARR and approaching a hire, scale, or expansion decision | One-page risk summary with specific constraints before capital is deployed | $999 |
| Revenue Due Diligence | Company is 60 to 90 days from initiating Series A or B conversations | Full investor-grade commercial analysis including repeatability and scalability assessment | $2,499 |